Palladia is a tyrosine kinase inhibitor designed to target and kill cancer cells while cutting off the blood supply to tumors. It is particularly noted for:

: Unlike traditional chemotherapy, it specifically targets certain proteins involved in tumor growth.

: It has been a cornerstone of canine oncology since its approval in 2009, offering a much brighter future for breeds prone to cancer, such as Golden Retrievers. Navigating the Challenges of Treatment

: Statistical data suggests that the chance of the drug working effectively can be lower than 30% in some cases.

The Palladia Dilemma: Balancing Hope and Quality of Life in Canine Cancer Treatment